Oropharyngeal Cancer - Pipeline Insight, 2024

This “Oropharyngeal cancer - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Oropharyngeal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Oropharyngeal cancer Understanding

Oropharyngeal cancer: Overview

Oropharyngeal cancer is cancer in the oropharynx, which is the middle part of your throat (pharynx). The oropharynx includes the back one-third of the tongue, tonsils, soft palate and the side and back walls of the throat. Oropharyngeal cancer is a type of head and neck cancer that accounts for about 18,000 newly diagnosed cases in the U.S. every year. Most oropharyngeal cancers are squamous cell carcinomas, meaning that the cancer is affecting your squamous cells, which are thin flat cells found in the lining of most of your organs. And although rare, lymphoma, or cancer affecting cells in the lymphatic system, can also occur at the base of the tongue and tonsils, which are made up of lymph tissue. Symptoms include a sore throat that doesn’t go away; a lump in the throat, mouth or neck; coughing up blood; white patch in the mouth and other symptoms. The stages of oropharyngeal cancer span from Stage I (best prognosis) to Stage IV (worst prognosis). Oropharyngeal cancer diagnosis often begins with a physical exam conducted by doctor, or sometimes dentist, to check for any signs of abnormality such as a sore or lump in mouth or swollen lymph nodes in neck. Treatment for oropharyngeal cancer depends on several factors, including but not limited to: type of cancer, size of the tumor and location of the cancer, lymph nodes, speech and swallow function, and the patient’s overall medical condition.

Oropharyngeal cancer - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Oropharyngeal cancer pipeline landscape is provided which includes the disease overview and Oropharyngeal cancer treatment guidelines. The assessment part of the report embraces, in depth Oropharyngeal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Oropharyngeal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Oropharyngeal cancer R&D. The therapies under development are focused on novel approaches to treat/improve Oropharyngeal cancer.

Oropharyngeal cancer Emerging Drugs Chapters

This segment of the Oropharyngeal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Oropharyngeal cancer Emerging Drugs

Cisplatin: AstraZenecaCisplatin works by stopping the cancer cells from multiplying. It does this by binding together the strands of the cells' genetic material, DNA. Cisplatin binds to the N7 reactive center on purine residues and as such can cause deoxyribonucleic acid (DNA) damage in cancer cells, blocking cell division and resulting in apoptotic cell death. The drug is being evaluated in Phase III clinical trials in combination with Durvalumab for the treatment of patients with Oropharyngeal cancer.

ISA101B: ISA PharmaceuticalsISA101 consists of 12 synthetic long peptides (25 to 35 amino acids long) derived from the E6 and E7 oncogenic proteins of the HPV 16 virus, a strain responsible for over 50% of human cervical cancers and cervical intra-epithelial neoplasias, more than 85% of HPV-positive head and neck cancers, and similar substantial percentages of other premalignant and malignant HPV-induced lesions (such as VIN, vulvar cancer, AIN and anal cancer). It is currently administered either subcutaneously or intradermally. The drug is currently in Phase II stage of development for the treatment of patients with Oropharyngeal cancer.

Oropharyngeal cancer: Therapeutic Assessment

This segment of the report provides insights about the different Oropharyngeal cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Oropharyngeal cancer

There are approx. 10+ key companies which are developing the therapies for Oropharyngeal cancer. The companies which have their Oropharyngeal cancer drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Oropharyngeal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Oropharyngeal cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Oropharyngeal cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Oropharyngeal cancer drugs.

Oropharyngeal cancer Report Insights

• Oropharyngeal cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Oropharyngeal cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Oropharyngeal cancer drugs?
• How many Oropharyngeal cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Oropharyngeal cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Oropharyngeal cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Oropharyngeal cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.